3月3日 - ** 药物开发商Syndax Pharmaceuticals SNDX.O股价下跌5%，至14.86美元
** 公司第四季度净亏损9420万美元，去年同期为7250万美元
** 第四季度运营支出为9640万美元，去年同期为7791万美元
** 公司报告其首个商业产品 Revuforj（化学名称为 revumenib）的第四季度销售额为 770 万美元，该产品用于治疗一种血癌。
** 预计 2025 年第二季度，revumenib 用于治疗一种始于骨髓的癌症的产品将获得监管部门的批准
** SNDX的股价在过去12个月中下跌了35%。
(为便利非英文母语者，路透将其报导自动化翻译为数种其他语言。由于自动化翻译可能有误，或未能包含所需语境，路透不保证自动化翻译文本的准确性，仅是为了便利读者而提供自动化翻译。对于因为使用自动化翻译功能而造成的任何损害或损失，路透不承担任何责任。)
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.